We are live on
!
Find out more
CC
Commodore Capital Portfolio holdings
AUM
$1.68B
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter
Est. Return
+40.89%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
-$49.5M
(-2.9%)
Cap. Flow
-$478M
Cap. Flow
% of AUM
-28.49%
Top 10 Holdings %
Top 10 Hldgs %
68.18%
Holding
41
New
5
Increased
6
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$55.6M |
| 2 |
Editas Medicine
EDIT
|
+$26M |
| 3 |
EyePoint Inc
EYPT
|
+$23.7M |
| 4 |
InflaRx
IFRX
|
+$13.7M |
| 5 |
Assembly Biosciences
ASMB
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVL
Nuvalent
NUVL
|
+$78.9M |
| 2 |
Spyre Therapeutics
SYRE
|
+$77.8M |
| 3 |
Relay Therapeutics
RLAY
|
+$72.6M |
| 4 |
Erasca
ERAS
|
+$51.4M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.36% |
| 2 | Financials | 0.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
SAB Biotherapeutics
SABS
$317M
| $11.2M | 0.67% |
2,870,000
-1,531,500
| -35% | -$5.7M |
|
27
Inhibikase Therapeutics
IKT
$336M
| $11M | 0.65% |
5,397,488
| – | – |
|
28
Relmada Therapeutics
RLMD
$436M
| $9.86M | 0.59% |
1,425,000
+791,099
| +125% | +$5.53M |
|
29
PepGen
PEPG
$218M
| $8.05M | 0.48% |
4,475,000
| – | – |
|
|
RACC
30
Research Alliance Corp III
RACC
$106M
| $5.35M | 0.32% |
+500,000
| New | +$5.21M |
|
|
HLXC
31
Helix Acquisition Corp III
HLXC
$238M
| $5.32M | 0.32% |
500,000
| – | – |
|
|
LONA
32
LeonaBio Inc
LONA
$66.3M
| $4.27M | 0.25% |
464,398
| – | – |
|
33
VistaGen Therapeutics
VTGN
$10.5M
| $630K | 0.04% |
+2,788,620
| New | +$1.68M |
|
34
Corvus Pharmaceuticals
CRVS
$1.12B
| – | – |
-2,258,735
| Closed | -$33M |
|
|
35
Erasca
ERAS
$5.49B
| – | – |
-3,175,000
| Closed | -$51.4M |
|
36
Karyopharm Therapeutics
KPTI
$38.3M
| – | – |
-1,950,000
| Closed | -$10.9M |
|
37
Nurix Therapeutics
NRIX
$2.73B
| – | – |
-2,275,000
| Closed | -$35.3M |
|
38
Ocular Therapeutix
OCUL
$2.52B
| – | – |
-2,575,000
| Closed | -$21.8M |
|
39
Palisade Bio
PALI
$357M
| – | – |
-7,181,062
| Closed | -$12.6M |
|
|
SLNO
40
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-652,432
| Closed | -$21.8M |
|
|
41
Xenon Pharmaceuticals
XENE
$5.71B
| – | – |
-825,000
| Closed | -$48M |
|
Similar funds
TNBTD
PWMAG
SH
CC
BCLSI
TP
ICM
HCA
Commodore Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Commodore Capital held 41 positions worth $1.68B, down 2.9% from $1.73B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Commodore Capital withdrew a net $478M in Q2 2026, closing 8 positions and reducing 9 holdings. Its most notable exit was Erasca, an estimated $51.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Commodore Capital opened a new position in Tango Therapeutics worth $70.3M.
- Commodore Capital's largest Q2 2026 buy was Tango Therapeutics: 2,250,000 shares worth $70.3M.
- Commodore Capital added most to EyePoint Inc in Q2 2026, an estimated $23.7M increase.
- Commodore Capital's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $78.9M.
- Commodore Capital fully exited Erasca in Q2 2026, selling an estimated $51.4M.
- Commodore Capital's ten largest holdings make up 68% of its $1.68B portfolio in Q2 2026.
- Commodore Capital opened 5 new positions and closed 8 in Q2 2026.
- Commodore Capital's portfolio value fell 2.9% quarter-over-quarter to $1.68B.
Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.